Pancreatic Cancer Research

ResearcherConsejo Nacional de Investigaciones Científicas y TécnicasActive in the last 2 years

Daniela Laura Papademetrio

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3419-5614; OpenAlex author ID A5042958390. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 5 papers

Papers 9

  1. Type I interferons modulate autophagy to shape gemcitabine response in pancreatic cancer cells. Last author DOI 10.1002/2211-5463.70342↗
  2. Stage-resolved gene drivers of pancreatic ductal adenocarcinoma progression and therapeutic vulnerabilities. Co-author DOI 10.1016/j.isci.2026.115164↗
  3. Pathway-driven therapeutic stratification in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2026.102920↗
  4. Small CD63 + CD81+ extracellular vesicles induce autophagy via the FOXO3a pathway in pancreatic cancer cells during starvation. Co-author DOI 10.1038/s41598-026-52731-0↗
  5. In Vitro Evaluation of Natural Sesquiterpene Lactones and Naphthoquinones Against Pancreatic Ductal Adenocarcinoma Cells. Last author DOI 10.3390/molecules31061014↗
  6. [The mRNA vaccine for the treatment of pancreatic cancer is here to stay]. Co-author PMID 37582144↗
  7. Sesquiterpene Lactones as Promising Candidates for Cancer Therapy: Focus on Pancreatic Cancer. Last author DOI 10.3390/molecules27113492↗
  8. Autophagy-Mediated Exosomes as Immunomodulators of Natural Killer Cells in Pancreatic Cancer Microenvironment. Co-author DOI 10.3389/fonc.2020.622956↗
  9. Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy. Co-author DOI 10.1007/s11523-015-0388-3↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. María Noé Garcia · 7 shared papers, 2020–2026 · strength 1.49
  2. Daniel Grasso · 7 shared papers, 2020–2026 · strength 1.49
  3. Élida Álvarez · 4 shared papers, 2016–2026 · strength 0.81
  4. Oscar Mazza · 3 shared papers, 2023–2026 · strength 0.57
  5. María Eugenia Pasqualini · 3 shared papers, 2023–2026 · strength 0.57
  6. Agustín Yaneff · 3 shared papers, 2023–2026 · strength 0.57
  7. Nicolas Alejandro Fraunhoffer · 3 shared papers, 2023–2026 · strength 0.57
  8. Eduardo Chuluyán · 3 shared papers, 2023–2026 · strength 0.57
  9. Juan Iovanna · 3 shared papers, 2023–2026 · strength 0.57
  10. Nelson Dusetti · 3 shared papers, 2023–2026 · strength 0.57
  11. Nadia Talin Mirakian · 2 shared papers, 2022–2026 · strength 0.45
  12. Laura Cecilia Laurella · 2 shared papers, 2022–2026 · strength 0.45
  13. Jonathan Garnier · 2 shared papers, 2026 · strength 0.42
  14. Brice Chanez · 2 shared papers, 2026 · strength 0.42
  15. Ana Sahores · 2 shared papers, 2023–2026 · strength 0.35
  16. Lucy Elena Bonilla · 1 shared paper, 2026 · strength 0.28
  17. Analía Meilerman Abuelafia · 1 shared paper, 2026 · strength 0.21
  18. Pascal R. Hammel · 1 shared paper, 2026 · strength 0.21
  19. Betina González · 1 shared paper, 2023 · strength 0.14
  20. Carlos Alberto Davio · 1 shared paper, 2023 · strength 0.14
  21. Patricia Santofimia‐Castaño · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.